Top Page
Concord Healthcare Group Co., Ltd. Class H
(2453)
Concord Healthcare Group Co., Ltd. Class H (2453) vs. iShares MSCI Hong Kong ETF (EWH)
Concord Healthcare Group Co., Ltd. Class H Business Overview & Revenue Model
Concord Healthcare Group Co., Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 388.31M | 538.65M | 549.08M | 567.06M | 186.89M |
| Gross Profit | -67.25M | -65.09M | -197.46M | -92.76M | -17.27M |
| EBITDA | -194.46M | -172.58M | -224.65M | -287.02M | -190.41M |
| Net Income | -443.22M | -373.09M | -629.59M | -984.17M | -655.41M |
Balance Sheet | |||||
| Total Assets | 5.91B | 5.24B | 6.08B | 6.66B | 5.90B |
| Cash, Cash Equivalents and Short-Term Investments | 337.12M | 49.23M | 142.02M | 166.47M | 503.70M |
| Total Debt | 3.21B | 2.60B | 2.94B | 7.42B | 5.99B |
| Total Liabilities | 4.01B | 3.37B | 3.84B | 8.08B | 6.52B |
| Stockholders Equity | 1.65B | 1.60B | 1.89B | -1.91B | -804.03M |
Cash Flow | |||||
| Free Cash Flow | -511.38M | 18.11M | -366.55M | -584.24M | -915.43M |
| Operating Cash Flow | -185.96M | 201.85M | -267.83M | 45.87M | -51.85M |
| Investing Cash Flow | -668.09M | -182.34M | -117.48M | -1.14B | -960.19M |
| Financing Cash Flow | 1.02B | -105.43M | 374.16M | 749.53M | 1.42B |
Concord Healthcare Group Co., Ltd. Class H Technical Analysis
Concord Healthcare Group Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$368.44M | 8.57 | 5.95% | 12.17% | 0.81% | 27.55% | |
68 Neutral | HK$1.72B | 5.33 | 24.13% | 4.17% | -3.85% | -19.28% | |
67 Neutral | HK$9.50B | 14.61 | 9.30% | ― | 7.28% | -13.77% | |
64 Neutral | HK$598.57M | 36.02 | 1.07% | 8.94% | -1.20% | -87.51% | |
59 Neutral | HK$410.00M | 7.90 | 8.82% | 2.63% | -10.82% | -44.11% | |
58 Neutral | HK$21.35B | 22.36 | -16.35% | 14.64% | 7.50% | -107.03% | |
45 Neutral | ― | -27.35% | ― | -29.41% | -16.52% |
Concord Healthcare Group Co., Ltd. Class H Corporate Events
Concord Healthcare Group Co., Ltd. announced that its subsidiary, Guangzhou Concord Cancer Center, completed China’s first proton therapy for choroidal malignant melanoma. This advancement provides a new eye-preserving treatment option, avoiding the traditional method of enucleation, and marks a significant milestone in the field of intraocular malignancy treatment in China.
Concord Healthcare Group Co., Ltd. has announced strategic adjustments to its operations to prioritize its proton therapy services, which are seen as a core business line with high growth potential. The company has streamlined its operations by closing or downsizing loss-making services at Guangzhou Hospital and reducing the procurement of certain pharmaceuticals. Additionally, the company has ceased operations at the Guangzhou Outpatient Center, Datong Hospital, and Internet Hospital due to underperformance exacerbated by the macroeconomic downturn. These measures have allowed Concord Healthcare to allocate resources more effectively towards the successful launch of its proton therapy center in December 2024, which is now fully operational.
Concord Healthcare Group Co., Ltd. announced a change in the members of its controlling shareholders. Shanghai Xinhe, previously a member of the controlling shareholders, will no longer hold this status following a decision to optimize business decision-making. Despite this change, Dr. Yang and entities controlled by him remain the controlling shareholders, maintaining significant voting rights and share capital in the company.
Concord Healthcare Group Co., Ltd. has successfully completed the placement of 18,600,000 new H shares under a general mandate, raising approximately HK$93.94 million. The proceeds will be used for procuring medical equipment, repaying loans, and supplementing working capital, with the shareholding structure of the company seeing an increase in total issued shares.
Concord Healthcare Group Co., Ltd. has entered into a Placing Agreement to issue 18,600,000 new shares at a price of HK$5.38 each, representing a discount to recent market prices. This move is expected to generate approximately HK$93.94 million in net proceeds, which will enhance the company’s financial position without requiring shareholder approval, as the shares are issued under a General Mandate.
Concord Healthcare Group Co., Ltd. held its Annual General Meeting (AGM) on May 27, 2025, where shareholders approved all proposed resolutions, including the reports of directors and the supervisory committee, financial statements, and the 2024 annual report. Additionally, the meeting saw the election of directors and supervisors, appointment of senior management, and approval of the budget plan for 2025. The unanimous approval of these resolutions, with no votes against, underscores strong shareholder support and positions the company for continued stability and growth in the healthcare sector.
Concord Healthcare Group Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board has established several committees, including the Audit Committee, the Remuneration and Appraisal Committee, and the Nomination Committee, to strengthen its governance framework. This announcement underscores the company’s commitment to robust corporate governance, potentially impacting its operational efficiency and stakeholder confidence.
Concord Healthcare Group Co., Ltd. has officially released its self-developed large language model (LLM) for proton therapy, marking a significant advancement in precise tumor diagnosis and treatment. This model, the first of its kind in China, has been successfully deployed at Guangzhou Concord Cancer Hospital, where it has demonstrated notable efficacy and reduced side effects in patient treatments. The development of this LLM is based on the company’s extensive data and expertise in tumor diagnosis, integrating thousands of radiotherapy cases and professional literature to enhance its capabilities. This advancement positions Concord Healthcare as a leader in the proton therapy field, potentially impacting its market standing and offering significant benefits to stakeholders.
Concord Healthcare Group Co., Ltd. announced that its controlling shareholder, Shanghai Medstar, has increased its shareholding by purchasing a total of 95,400 H shares from the open market. This move, which represents approximately 0.01% of the total issued shares, reflects Shanghai Medstar’s confidence in the company’s future prospects and supports its ongoing development. The company has been granted a waiver to maintain a lower public float percentage, with at least 20.92% of its shares held by the public following this transaction.
Concord Healthcare Group Co., Ltd. announced that its controlling shareholder, Shanghai Medstar, has increased its shareholding by purchasing 45,600 H shares from the open market. This move, reflecting confidence in the company’s future prospects, represents approximately 0.01% of the total issued shares. The company has also been granted a waiver by the Hong Kong Stock Exchange to maintain a lower public float percentage, ensuring at least 20.94% of shares are held by the public. This development indicates strong support from major stakeholders and potential for further investment.
Concord Healthcare Group Co., Ltd. has announced its upcoming Annual General Meeting (AGM) scheduled for May 27, 2025, where key resolutions will be considered. These include the approval of financial statements, remuneration for directors and supervisors, budget plans, and the election of board members and supervisors for the fourth session. The AGM will also address the purchase of indemnity insurance for senior management and the decision not to pay a final dividend, which could impact stakeholders’ expectations regarding financial returns.